[DOWNLOAD]⚡ Cardiovascular Research PCSK9 Therapeutic Target Cardiovascular Disease

#BESTSELLER
New Cardiovascular Research: PCSK9 as a New Therapeutic
Target for Cardiovascular Disease
Sinopsis :
Cardiovascular disease (CVD) is one of the major diseases
which causing premature death in the world. Plasma LDL level
is a major determinant of CVD. Statin drugs prove to be big
success on reducing 30-40% cholesterol in some people, yet
fail far short in others with initial high value of cholesterol. they
need 2 or even 3 different drugs to reach the level &lt100mgdL
and with high risk of side effects of statin. Consequently, there
is a need to develop new cholesterol-lowering drug.Recent
genetic studies have shown, one of the key genes, Proprotein
convertase subtilisin/kexin type 9(PCSK9), plays a critical role
in cholesterol metabolism by controlling the level of low-density
lipoprotein receptor (LDLr). In the chapter I, introduction, we
explain why study PCSK9 is important to human health. In

chapter II . we described a high throughput assay to identify
leading inhibitor compound for PCSK9..In the Chapter III, we
describe a shotgun proteomic analysis of potential binding
partners of PCSK9, some of them such as E38 ubiquitin ligase
c-IAP1 could be significant modulators of PCSK9 function. In
chapter IV, we discussed the possible role of the PCSK9 in the
infectious disease. In Chapter V, we gave the latest progress
using PCSK9 inhibitors, including using anti-PCSK9 antibody
and anti/PCSK9 SiRNA to treat cardiovascular diseases. The
best example of the SiRNA inhibition of PCSK9 is the drug,
called Inclisiran, developed by the drug company Novartis. The
drug can be administrated by injection twice a year to reduce
the cholesterol level by 50%, which is already proved by the
UK drug agency NICE. In Chapter VI, we discussed the
possibility colchicine, PCSK9 and infection disease in TNFalpha-mediated
cytokine storm in COVID-19.